SHARE

Treatment for fatal diseases such as Alzheimer and cancer poses a challenge to medical world. There is huge market waiting to be unearthed. Therefore, it comes as a no surprise that Anavex Life Sciences Corp (OTCMKTS:AVXL) is actively directly its resources to develop promising treatment. The company recently presented clean trial results of two of its lead drug candidates that are in the early phases of clinical development. The early indications are promising and their revenue potential is also not in doubt.

The details

At the International Conference on neurological disorders, representatives of the company grabbed the opportunity to disclose the world what they are working on and how the progress has been so far. Anavex presented preliminary results of ANAVEX 3-71 and ANAVEX 2-73, its two main drug candidates that just finished the initial studies and are advancing in next development stage. In fact, one of the lead drug candidates is already in Phase 2a study having left Phase 1 trial with clean trial results. The company stated that it will update public and shareholders on the progress it is achieving in the development of ANAVEX 2-73 and ANAVEX 3-71.

ANAVEX 3-71

Preclinical evaluation of ANAVEX 3-71 showed exceptional preclinical advantages in fighting Alzheimer’s disease. The results showed pioneering action mechanism that resulted in the improvement of both neuroprotection and cognition. The other positive results were the drug’s ability to minimize mitochondrial dysfunctions and inflammation. Anavex’s ANAVEX 3-71 is offering all the interesting promise of being an effective cure for both cognitive impairments and disease modifications.

ANAVEX 2-73

The second lead candidate also focuses on treatment of Alzheimer. The drug is undergoing Phase 2a trial. The Phase 1 results were impressive, which makes the management hopeful for promising results in the future studies. In addition to fighting Alzheimer’s, ANAVEX 2-73 is also showing promising results to cure other CNS indications.

LEAVE A REPLY